Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Dow Jones Futures: Jobs Report Tests 'Soft Landing' Market Rally; Tesla Stock Split Approved

The indexes were quiet before the July jobs report tests the Fed's soft landing. Tesla shareholders OK'd a 3-for-1 stock split.

Investors Business Daily

What Are Whales Doing With Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx

Amgen narrowed its outlook for 2022 sales after its second-quarter beat. But Amgen stock fell just a fraction on Friday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Gold Tops 1,800; Alibaba Reports Upbeat Results

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday

Benzinga

Stock Market In Consolidation; Energy Sells Off For Second Day

The Nasdaq composite is showing minor strength, higher by less than 0.1%.

Investors Business Daily

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Benzinga

Nasdaq Edges Higher; Crude Oil Falls Sharply

U.S. stocks pared some losses midway through trading, with the Nasdaq Composite turning higher on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June

U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Thursday.

Benzinga

Amgen Aims To Stanch Generic Losses With $3.7 Billion ChemoCentryx Buyout

Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage.

Investors Business Daily

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1

CNBC

Benzinga

Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points

Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.

Investors Business Daily

Highly Rated Amgen Stock Near Buy Zone With Earnings Due

Amgen is near a buy zone with earnings due on or around Aug. 4.

Investors Business Daily

Amgen Whale Trades For July 12

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Could The Next CRISPR From Verve, Beam Signal The End To High Cholesterol?

Verve Therapeutics said Tuesday it edited the genes of someone with high cholesterol. The first-ever move could push VERV stock higher.

Investors Business Daily

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.

StockNews.com

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

Benzinga

Check Out What Whales Are Doing With AMGN

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Investors Business Daily

Here Are The 5 Best Dow Jones Stocks So Far This Year Amid Market Sell-Off

Chevron is well off its June peak, but is still the top Dow Jones stock performer so far in 2022 amid a brutal market sell-off.

Benzinga

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of $130.40 billion.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Benzinga

How Is The Market Feeling About Amgen?

Amgen's (NASDAQ:AMGN) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 3.54% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion.

1 … 10 11 12 13

People

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.